Robert Weisman

Weisman covers the healthcare and life sciences industries for the Business section. He was a business reporter and editor for the Hartford Courant and the Seattle Times before joining the Globe in 2000.

Latest stories

Sarepta seeks to raise $225 million in stock sale

By , Globe Staff

Tapping capital markets at an opportune time, Sarepta Therapeutics Inc. said Wednesday it will seek to raise up to $225 million in a stock sale as it moves to launch its first approved drug and finance research and clinical studies of several other treatments.

Eleven Biotherapeutics buys Canadian company

By , Globe Staff

The Cambridge developer of cancer drugs paid stock valued at $13.5 million for Toronto-based Viventia Bio Inc.

Moderna bets big with $110 million drug plant in Norwood

By , Globe Staff

The new 200,000-square-foot biomanufacturing facility, scheduled to open in early 2018, will employ more than 200 workers.

Sarepta is now one of the hottest stars in Kendall Square

By , Globe Staff

After a surprise approval of its experimental drug for Duchenne muscular dystrophy, Sarepta’s stock closed near a record high Tuesday.